Pfizer and its German partner on Tuesday said they submitted data concerning results of a COVID-19 vaccine trial in children as young as 5. Pfizer and BioNTech sent the data to the U.S. Food and Drug Administration (FDA). The data is from a Phase 2/3 trial examining the companies’ COVID-19 shot in children 5 to 11, an age group that cannot currently get a COVID-19 vaccine in the United States. The companies say the data showed a favorable safety profile and that the vaccine triggered antibody responses in the children. The kids were given a two-dose regimen of 10 micrograms each. The companies have not released full results from the trial. Results for children 6 months old to 4 years of age, another group being studied in the trial, are expected to be released in the fourth quarter of this year. The companies are planning to submit the trial data …